SCHEMBL25753466

SCHEMBL25753466

Cc1ncsc1C(=O)/C=C/c1ccc(-c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
ALDH1A1 P00352 3/20 0.55
LMNA P02545 2/20 0.55
KMT2A Q03164 2/20 0.55
RAB9A P51151 1/20 0.55
ATM Q13315 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
HDAC2 Q92769 1/20 0.47
CYP3A4 P08684 2/20 0.46
HPGD P15428 1/20 0.46
NQO2 P16083 3/20 0.44
ALOX5 P09917 1/20 0.43
BCHE P06276 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
CYP1B1 Q16678 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25753449 0.92 MAPT (0.57) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL26248943 0.86 MAPT (0.54) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL28497749 0.85 JAK2 (0.56) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL25753458 0.83 MAPT (0.55) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL25753450 0.82 F3 (0.57) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL25753656 0.81 KDM4E (0.51) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL26248945 0.78 MAOA (0.52) MAPTALDH1A1LMNAKMT2ARAB9A
SCHEMBL25753461 0.77 PTGS2 (0.49) MAPTALDH1A1LMNARAB9AKDM4E
SCHEMBL25753464 0.77 PTGS2 (0.49) MAPTALDH1A1LMNAKDM4EPKM
SCHEMBL25753457 0.76 MAOB (0.53) MAPTALDH1A1LMNAKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-09-07 US disclosed
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-09-07 US disclosed
EP-4205741-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR CYP2E1, CYP11B1, CYP27A1 MAPT 1097/4885ALDH1A1 434/4885LMNA 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.